Precisionantibody/AntiHRP2 Sample Packs (Clones 11E10 / 6C8 / 10F5 / 12D4)/CAT0020600502/1 Ea

This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!
Clipboard, Search History, and several other advanced features are temporarily unavailable.
1 Radioimmune and Inorganic Chemistry Section, Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Building 10, Room B3B69, Bethesda, MD 20892Z-1002, USA.
1 Radioimmune and Inorganic Chemistry Section, Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Building 10, Room B3B69, Bethesda, MD 20892Z-1002, USA.
Extract: Hybridoma/monoclonal antibody (mAb) technology as described in Kohler and Milsteins work resurrected Ehrlichs century old concept of "magic bullets." This seminal publication described fusion of a plasmacytoma (tumor of activated B lymphocytes) with spleen cells and subsequent isolation of hybrids that secreted mAb with pre-defined specificity. Generation of mouse mAbs against tumor-associated antigens became a focus in the 1980s. Pre-clinical studies provided proof-of-concept for the potential of mAbs for therapy although inherent limitations of these models demonstrated discordance in predictability of actual efficacy. Clinical investigations also illustrated deficiencies; foremost, an inevitable immune response, i.e., the production of human anti-murine immunoglobulin antibodies (HAMA). Other limitations included (1) inadequate tumor dose delivery; (2) insufficient activation of effector function(s); (3) slow blood clearance; (4) low affinity and avidity; (5) normal organ targeting; (6) tumor antigen heterogeneity; and (7) insufficient tumor penetration. Most of these were handled with genetic engineering or chemical modification, but some obstacles remained. HAMA production has been addressed by chimerization (combining portions of mouse and human antibodies) or complete humanization (grafting only the key antigen-binding portions of mouse antibody to a human antibody framework) of the mAb.

Xu X, Clarke P, Szalai G, Shively JE, Williams LE, Shyr Y, Shi E, Primus FJ. Xu X, et al. Cancer Res. 2000 Aug 15;60(16):4475-84. Cancer Res. 2000. PMID: 10969795
Ray GL, et al. Pharmaceuticals (Basel). 2011 Dec 22;5(1):1-15. doi: 10.3390/ph5010001. Pharmaceuticals (Basel). 2011. PMID: 22229017 Free PMC article.

Neuromics Antib... 我公司国内总代理,华东地区代理Neuromics Antibodies专业经营进... 更多详情+
CRIPT Antibody 欲购买CRIPT Antibody抗体，请致电咨询，现货促销,为您提供周到的产品服务及高品... [详情]

acris antibodies公司【@拜力生物】,上海拜力进口试剂耗材解决方案... 更多详情+ antibodies上等代理@... antibodies上等代理@拜力,antibodies公司代理。本页是上海拜力...

Extract: Hybridoma/monoclonal antibody (mAb) technology as described in Kohler and Milstein's work resurrected Ehrlich's century old concept of "magic bullets." T...